Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors
European Journal of Surgical Oncology, 06/03/09
Fiore M et al. - In unresectable or locally advanced gastrointestinal stromal tumor (GISTs), preoperative imatinib mesylate (IM) is a useful tool both to improve resectability and reduce surgical morbidity.
Methods- Aim was to investigate the effect of preoperative IM in pts with unresectable or locally advanced primary GIST
- From Jan 2003 to Jan 2008, all pts affected by bulky localized GIST were considered for preoperative IM with cytoreductive intent
- Clinical, pathological and molecular characteristics were assessed and the rate of response recorded
- Progression-free survival (PFS) was calculated according to Kaplan–Meier analysis
- 15 pts: 1 esophageal, 7 gastric, 3 duodenal, 4 rectal GISTs received preoperative IM for a median of 9 mo
- All pts had tumor shrinkage, with a median size reduction of 34%
- 1 patient had radiological CR
- In all cases an improvement of the originally planned surgical procedure was obtained:
- 3 pts initially considered unresectable underwent complete surgery
- 7 pts with initial indication for extensive surgery were more conservatively operated on
- 4 pts initially deemed at high perioperative risk underwent safe surgery
- PFS at 3 yrs from IM onset was 77%
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Surgical management of colorectal liver metastases
Community Oncology , 10/09/09
Treatment of Barretts esophagus with high-grade dysplasia and intramucosal adenocarcinoma
Expert Review of Gastroenterology & Hepatology, 10/13/09
Novel agents for the treatment of adenocarcinoma of the pancreas
Expert Review of Anticancer Therapy, 10/22/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
The Lancet - Early Online Publication, 10/19/09
Novel agents for the treatment of adenocarcinoma of the pancreas
Expert Review of Anticancer Therapy, 10/22/09
Methotrexate for maintenance of remission in Crohn's disease
Cochrane Reviews, 10/27/09
Sponsor
Article Search
Sponsor


See Latest Articles


